ADCC-enhancement for innovative cancer therapy, produced via ProBioGen’s accelerated CMC development path.
Berlin, Germany, and South San Francisco, CA, USA
ProBioGen AG and Tizona Therapeutics, Inc. have signed a commercial license and service agreement for cell line and process development. Under the Agreement ProBioGen will develop Tizona’s immuno-oncology antibody up to GMP manufacturing, applying ProBioGen’s proprietary GlymaxX® cell line to boost the antibody’s ADCC anti-tumor activity. The program will follow ProBioGen’s integrated and accelerated development path which allows selecting superior, stable producer clones with robust and excellent process features in a significantly reduced time, facilitating the earlier onset of clinical trials. Manufacturing of clinical study material will be conducted at ProBioGen’s new facility which will house two additional 1,000L single-use bioreactors in its GMP suites.
Volker Sandig, ProBioGen’s CSO commented “We were impressed by the scientific approach and quality of work which Tizona has invested into this product candidate already, and we are looking forward to combining our expertise with that of Tizona for this very promising product candidate.”
René Brecht, VP Process Science and Manufacturing at ProBioGen added “Our accelerated CMC development path allows us to choose clones with optimal product and manufacturing characteristics right from the beginning, resulting in simplified scale-up and reduced time lines.”
Tizona’s COO, Jeremy Bender, commented: We were seeking a high quality service provider with a proven track record and a robust ADCC enhancement technology for our project, and ProBioGen’s package of technical and scientific expertise, timelines, financial terms and, importantly, people behind it, were a compelling combination.”